Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1998 Dec 1;336(Pt 2):299–303. doi: 10.1042/bj3360299

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.

J M Bruneau 1, C M Yea 1, S Spinella-Jaegle 1, C Fudali 1, K Woodward 1, P A Robson 1, C Sautès 1, R Westwood 1, E A Kuo 1, R A Williamson 1, E Ruuth 1
PMCID: PMC1219871  PMID: 9820804

Abstract

Leflunomide is currently in phase-III clinical trials for the treatment of rheumatoid arthritis. In this study, we have focused our efforts on the study of the mechanism of action of the active metabolite of leflunomide, A77 1726, in cells and tissue of human origin. The human high-affinity binding protein for radiolabelled A77 1726 was purified from solubilized U937 membranes by following the binding activity through the purification process and was characterized as the mitochondrial enzyme dihydro-orotate dehydrogenase (DHO-DH). The human and murine enzyme displayed identical pI and molecular mass values on SDS/PAGE (43 kDa), which contrasts notably with previous reports suggesting a molecular mass of 50 kDa for the human enzyme. DHO-DH activity was inhibited by A77 1726 and its analogue HR325 with similar potency in U937 and human spleen membrane preparations. HR325 was found to be anti-proliferative for phytohaemagglutinin-stimulated human peripheral blood mononuclear cells, at the same concentrations that caused accumulation of DHO and depletion of uridine. Supplementation of the cultures with exogenous uridine led to partial abrogation of the anti-proliferative effect. This is in line with our recent demonstration that the anti-proliferative effect in vitro of A77 1726 on lipopolysaccharide-stimulated mouse spleen cells was mediated by DHO-DH inhibition [Williamson, Yea, Robson, Curnock, Gadher, Hambleton, Woodward, Bruneau, Hambleton, Moss et al., (1995) J. Biol. Chem. 270, 22467-22472]. Thus, DHO-DH inhibition by A77 1726 and its analogues is responsible for the anti-proliferative effects in vitro of the compounds on human cells and is likely to be responsible for some of its effects in vivo.

Full Text

The Full Text of this article is available as a PDF (148.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett R. R., Dimitrijevic M., Mattar T., Zielinski T., Germann T., Rüde E., Thoenes G. H., Küchle C. C., Schorlemmer H. U., Bremer E. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions. 1991 Jan;32(1-2):10–21. doi: 10.1007/BF01983301. [DOI] [PubMed] [Google Scholar]
  2. Chen S. F., Perrella F. W., Behrens D. L., Papp L. M. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Cancer Res. 1992 Jul 1;52(13):3521–3527. [PubMed] [Google Scholar]
  3. Copeland R. A., Davis J. P., Dowling R. L., Lombardo D., Murphy K. B., Patterson T. A. Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Arch Biochem Biophys. 1995 Oct 20;323(1):79–86. doi: 10.1006/abbi.1995.0012. [DOI] [PubMed] [Google Scholar]
  4. Fairbanks L. D., Bofill M., Ruckemann K., Simmonds H. A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995 Dec 15;270(50):29682–29689. [PubMed] [Google Scholar]
  5. Greene S., Watanabe K., Braatz-Trulson J., Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol. 1995 Sep 7;50(6):861–867. doi: 10.1016/0006-2952(95)00255-x. [DOI] [PubMed] [Google Scholar]
  6. Hines V., Keys L. D., 3rd, Johnston M. Purification and properties of the bovine liver mitochondrial dihydroorotate dehydrogenase. J Biol Chem. 1986 Aug 25;261(24):11386–11392. [PubMed] [Google Scholar]
  7. Knecht W., Köhler R., Minét M., Löffler M. Anti-peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44-kDa protein from rat liver mitochondria. Eur J Biochem. 1996 Mar 1;236(2):609–613. doi: 10.1111/j.1432-1033.1996.00609.x. [DOI] [PubMed] [Google Scholar]
  8. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  9. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  10. Miller R. W., Curry J. R. Mammalian dihydroorotate--ubiquinone reducatse complex. II. Correlation with cytochrome oxidase, mode of linkage with the cytochrome chain, and general properties. Can J Biochem. 1969 Jul;47(7):725–734. doi: 10.1139/o69-110. [DOI] [PubMed] [Google Scholar]
  11. Minet M., Dufour M. E., Lacroute F. Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 1992 Nov 16;121(2):393–396. doi: 10.1016/0378-1119(92)90150-n. [DOI] [PubMed] [Google Scholar]
  12. Peters G. J., Kraal I., Pinedo H. M. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine. Br J Cancer. 1992 Feb;65(2):229–233. doi: 10.1038/bjc.1992.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rawls J., Kirkpatrick R., Yang J., Lacy L. The dhod gene and deduced structure of mitochondrial dihydroorotate dehydrogenase in Drosophila melanogaster. Gene. 1993 Feb 28;124(2):191–197. doi: 10.1016/0378-1119(93)90393-h. [DOI] [PubMed] [Google Scholar]
  14. Rotgeri A., Löffler M. Molecular cloning and sequence analyses of rat liver dihydroorotate dehydrogenase. Adv Exp Med Biol. 1994;370:693–697. doi: 10.1007/978-1-4615-2584-4_144. [DOI] [PubMed] [Google Scholar]
  15. Wessel D., Flügge U. I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984 Apr;138(1):141–143. doi: 10.1016/0003-2697(84)90782-6. [DOI] [PubMed] [Google Scholar]
  16. Williamson R. A., Yea C. M., Robson P. A., Curnock A. P., Gadher S., Hambleton A. B., Woodward K., Bruneau J. M., Hambleton P., Moss D. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem. 1995 Sep 22;270(38):22467–22472. doi: 10.1074/jbc.270.38.22467. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES